Compare NHC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHC | DNLI |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 1997 | 2017 |
| Metric | NHC | DNLI |
|---|---|---|
| Price | $189.06 | $18.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $35.82 |
| AVG Volume (30 Days) | 127.6K | ★ 1.3M |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | ★ 17.46 | N/A |
| EPS | ★ 5.66 | N/A |
| Revenue | ★ $1,517,781,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.90 |
| P/E Ratio | $33.38 | ★ N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $128.00 | $15.34 |
| 52 Week High | $248.20 | $27.30 |
| Indicator | NHC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 28.43 | 43.32 |
| Support Level | $186.65 | $18.24 |
| Resistance Level | $231.79 | $21.45 |
| Average True Range (ATR) | 6.70 | 0.94 |
| MACD | -1.64 | -0.10 |
| Stochastic Oscillator | 12.74 | 24.50 |
National Healthcare Corp provides long-term care facilities. Its principal business includes operating skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services and Home care and hospice services. The majority of revenue is derived from the Inpatient services segment.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.